Robert LeBoyer
Stock Analyst at Noble Capital Markets
(0.63)
# 3,371
Out of 4,666 analysts
16
Total ratings
28.57%
Success rate
-5.6%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Robert LeBoyer
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| GOVX GeoVax Labs | Maintains: Outperform | $6 → $10 | $2.61 | +283.14% | 2 | Aug 19, 2024 | |
| UNCY Unicycive Therapeutics | Initiates: Outperform | $6 | $0.51 | +1,077.86% | 1 | Feb 14, 2024 | |
| CVKD Cadrenal Therapeutics | Initiates: Outperform | $60 | $14.50 | +313.79% | 1 | Dec 18, 2023 | |
| ELDN Eledon Pharmaceuticals | Initiates: Outperform | $10 | $3.85 | +159.74% | 1 | Sep 27, 2023 | |
| MAIA MAIA Biotechnology | Initiates: Outperform | $14 | $2.23 | +527.80% | 1 | Feb 21, 2023 | |
| TNXP Tonix Pharmaceuticals Holding | Initiates: Outperform | $3,840 | $0.19 | +2,020,952.63% | 1 | Apr 18, 2022 | |
| LCTX Lineage Cell Therapeutics | Initiates: Outperform | $8 | $0.64 | +1,147.27% | 2 | Aug 19, 2021 | |
| PSTV Plus Therapeutics | Initiates: Buy | $120 | $1.19 | +9,984.03% | 1 | Jan 25, 2021 | |
| BNTC Benitec Biopharma | Downgrades: Neutral | n/a | $10.66 | - | 1 | Oct 5, 2020 | |
| AVXL Anavex Life Sciences | Initiates: Buy | $12 | $8.48 | +41.59% | 1 | Sep 28, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $16,500 | $0.12 | +13,349,414.56% | 1 | Aug 24, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $15.46 | - | 1 | Apr 10, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $15 | $1.57 | +856.27% | 2 | Mar 8, 2018 |
GeoVax Labs
Aug 19, 2024
Maintains: Outperform
Price Target: $6 → $10
Current: $2.61
Upside: +283.14%
Unicycive Therapeutics
Feb 14, 2024
Initiates: Outperform
Price Target: $6
Current: $0.51
Upside: +1,077.86%
Cadrenal Therapeutics
Dec 18, 2023
Initiates: Outperform
Price Target: $60
Current: $14.50
Upside: +313.79%
Eledon Pharmaceuticals
Sep 27, 2023
Initiates: Outperform
Price Target: $10
Current: $3.85
Upside: +159.74%
MAIA Biotechnology
Feb 21, 2023
Initiates: Outperform
Price Target: $14
Current: $2.23
Upside: +527.80%
Tonix Pharmaceuticals Holding
Apr 18, 2022
Initiates: Outperform
Price Target: $3,840
Current: $0.19
Upside: +2,020,952.63%
Lineage Cell Therapeutics
Aug 19, 2021
Initiates: Outperform
Price Target: $8
Current: $0.64
Upside: +1,147.27%
Plus Therapeutics
Jan 25, 2021
Initiates: Buy
Price Target: $120
Current: $1.19
Upside: +9,984.03%
Benitec Biopharma
Oct 5, 2020
Downgrades: Neutral
Price Target: n/a
Current: $10.66
Upside: -
Anavex Life Sciences
Sep 28, 2020
Initiates: Buy
Price Target: $12
Current: $8.48
Upside: +41.59%
Aug 24, 2020
Initiates: Buy
Price Target: $16,500
Current: $0.12
Upside: +13,349,414.56%
Apr 10, 2018
Downgrades: Neutral
Price Target: n/a
Current: $15.46
Upside: -
Mar 8, 2018
Initiates: Buy
Price Target: $15
Current: $1.57
Upside: +856.27%